While there are multiple tumor types where GAS6/AXL signaling has been implicated, we are initially evaluating AVB-500 in platinum resistant ovarian cancer. Ovarian cancer is the most deadly reproductive cancer in women, and more than 22,000 women are diagnosed with the disease each year in the U.S. This cancer mainly develops in older women. Many women with advanced ovarian cancer who receive standard-of-care ultimately relapse and develop drug-resistant disease. We are focused on addressing the high unmet need in this patient population and successfully completed a Phase 1b trial of AVB-500 in patients with platinum resistant ovarian cancer (NCT03639246). We have initiated and are recruiting for a registrational Phase 3 trial of AVB-500 in platinum resistant ovarian cancer (NCT04729608). Additionally, we have initiated and are recruiting for a Phase 1b/2 clinical trial of AVB-500 in patients with clear cell renal cell carcinoma (NCT04300140). In the future we hope to evaluate AVB-500 in combination with standard of care in a number of additional tumor types, including acute myeloid leukemia, triple negative breast cancer and pancreatic cancer.